![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CCNI |
Gene summary for CCNI |
![]() |
Gene information | Species | Human | Gene symbol | CCNI | Gene ID | 10983 |
Gene name | cyclin I | |
Gene Alias | CCNI1 | |
Cytomap | 4q21.1 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024RDH0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
10983 | CCNI | C46 | Human | Oral cavity | OSCC | 2.46e-40 | 1.37e+00 | 0.1673 |
10983 | CCNI | C51 | Human | Oral cavity | OSCC | 6.00e-16 | 1.23e+00 | 0.2674 |
10983 | CCNI | C57 | Human | Oral cavity | OSCC | 1.78e-50 | 2.06e+00 | 0.1679 |
10983 | CCNI | C06 | Human | Oral cavity | OSCC | 1.31e-29 | 2.44e+00 | 0.2699 |
10983 | CCNI | C07 | Human | Oral cavity | OSCC | 1.16e-08 | 1.50e+00 | 0.2491 |
10983 | CCNI | C08 | Human | Oral cavity | OSCC | 7.52e-66 | 1.93e+00 | 0.1919 |
10983 | CCNI | C86 | Human | Oral cavity | OSCC | 2.55e-07 | 1.57e+00 | 0.161 |
10983 | CCNI | C09 | Human | Oral cavity | OSCC | 1.83e-41 | 1.77e+00 | 0.1431 |
10983 | CCNI | LN22 | Human | Oral cavity | OSCC | 3.41e-30 | 2.06e+00 | 0.1733 |
10983 | CCNI | LN38 | Human | Oral cavity | OSCC | 6.51e-10 | 1.42e+00 | 0.168 |
10983 | CCNI | LN46 | Human | Oral cavity | OSCC | 4.20e-23 | 1.36e+00 | 0.1666 |
10983 | CCNI | LP15 | Human | Oral cavity | LP | 1.56e-17 | 1.86e+00 | 0.2174 |
10983 | CCNI | LP16 | Human | Oral cavity | LP | 6.57e-07 | 1.44e+00 | 0.1055 |
10983 | CCNI | LP17 | Human | Oral cavity | LP | 1.14e-20 | 2.15e+00 | 0.2349 |
10983 | CCNI | SYSMH1 | Human | Oral cavity | OSCC | 1.62e-11 | 6.32e-01 | 0.1127 |
10983 | CCNI | SYSMH2 | Human | Oral cavity | OSCC | 3.37e-26 | 1.29e+00 | 0.2326 |
10983 | CCNI | SYSMH3 | Human | Oral cavity | OSCC | 2.52e-21 | 1.13e+00 | 0.2442 |
10983 | CCNI | SYSMH4 | Human | Oral cavity | OSCC | 2.02e-07 | 4.53e-01 | 0.1226 |
10983 | CCNI | SYSMH5 | Human | Oral cavity | OSCC | 1.54e-03 | 5.68e-01 | 0.0647 |
10983 | CCNI | SYSMH6 | Human | Oral cavity | OSCC | 2.58e-32 | 1.31e+00 | 0.1275 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00447724 | Breast | DCIS | mitotic cell cycle phase transition | 46/1390 | 424/18723 | 6.16e-03 | 4.39e-02 | 46 |
GO:00447725 | Cervix | CC | mitotic cell cycle phase transition | 89/2311 | 424/18723 | 2.70e-07 | 1.12e-05 | 89 |
GO:00719007 | Cervix | CC | regulation of protein serine/threonine kinase activity | 75/2311 | 359/18723 | 2.76e-06 | 8.02e-05 | 75 |
GO:004477212 | Cervix | N_HPV | mitotic cell cycle phase transition | 22/534 | 424/18723 | 5.33e-03 | 3.84e-02 | 22 |
GO:0071900 | Colorectum | AD | regulation of protein serine/threonine kinase activity | 98/3918 | 359/18723 | 2.18e-03 | 1.73e-02 | 98 |
GO:00719001 | Colorectum | SER | regulation of protein serine/threonine kinase activity | 74/2897 | 359/18723 | 5.22e-03 | 3.96e-02 | 74 |
GO:00719002 | Colorectum | MSS | regulation of protein serine/threonine kinase activity | 93/3467 | 359/18723 | 2.98e-04 | 3.91e-03 | 93 |
GO:00719003 | Colorectum | FAP | regulation of protein serine/threonine kinase activity | 78/2622 | 359/18723 | 3.99e-05 | 8.48e-04 | 78 |
GO:00719008 | Endometrium | AEH | regulation of protein serine/threonine kinase activity | 61/2100 | 359/18723 | 6.11e-04 | 5.98e-03 | 61 |
GO:00447726 | Endometrium | AEH | mitotic cell cycle phase transition | 67/2100 | 424/18723 | 2.37e-03 | 1.78e-02 | 67 |
GO:007190013 | Endometrium | EEC | regulation of protein serine/threonine kinase activity | 62/2168 | 359/18723 | 8.17e-04 | 7.61e-03 | 62 |
GO:004477213 | Endometrium | EEC | mitotic cell cycle phase transition | 71/2168 | 424/18723 | 8.68e-04 | 7.97e-03 | 71 |
GO:00447729 | Esophagus | HGIN | mitotic cell cycle phase transition | 89/2587 | 424/18723 | 2.80e-05 | 7.21e-04 | 89 |
GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
GO:007190016 | Esophagus | ESCC | regulation of protein serine/threonine kinase activity | 227/8552 | 359/18723 | 1.12e-11 | 4.10e-10 | 227 |
GO:19040294 | Esophagus | ESCC | regulation of cyclin-dependent protein kinase activity | 69/8552 | 98/18723 | 6.04e-07 | 7.91e-06 | 69 |
GO:00000794 | Esophagus | ESCC | regulation of cyclin-dependent protein serine/threonine kinase activity | 66/8552 | 94/18723 | 1.24e-06 | 1.53e-05 | 66 |
GO:00447721 | Liver | Cirrhotic | mitotic cell cycle phase transition | 139/4634 | 424/18723 | 1.02e-04 | 1.06e-03 | 139 |
GO:007190011 | Liver | Cirrhotic | regulation of protein serine/threonine kinase activity | 110/4634 | 359/18723 | 6.19e-03 | 3.08e-02 | 110 |
GO:00447722 | Liver | HCC | mitotic cell cycle phase transition | 240/7958 | 424/18723 | 2.47e-09 | 6.84e-08 | 240 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CCNI | SNV | Missense_Mutation | rs779499819 | c.95N>A | p.Arg32Gln | p.R32Q | Q14094 | protein_coding | tolerated(0.29) | benign(0) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
CCNI | SNV | Missense_Mutation | novel | c.568N>A | p.Ala190Thr | p.A190T | Q14094 | protein_coding | deleterious(0.02) | benign(0.047) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.245C>T | p.Ala82Val | p.A82V | Q14094 | protein_coding | tolerated(0.06) | benign(0.248) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CCNI | SNV | Missense_Mutation | novel | c.122C>A | p.Ser41Tyr | p.S41Y | Q14094 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.790C>T | p.Pro264Ser | p.P264S | Q14094 | protein_coding | tolerated(0.11) | benign(0.376) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.430A>G | p.Thr144Ala | p.T144A | Q14094 | protein_coding | tolerated(0.11) | benign(0.006) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.491A>G | p.Gln164Arg | p.Q164R | Q14094 | protein_coding | tolerated(0.42) | benign(0.001) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.967N>T | p.Arg323Cys | p.R323C | Q14094 | protein_coding | deleterious(0.01) | possibly_damaging(0.465) | TCGA-A5-A0GR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | novel | c.886N>A | p.Pro296Thr | p.P296T | Q14094 | protein_coding | tolerated(0.05) | benign(0.196) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CCNI | SNV | Missense_Mutation | rs772326265 | c.845N>T | p.Ser282Phe | p.S282F | Q14094 | protein_coding | deleterious(0.01) | benign(0.03) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |